截至11月13日收盘，高压氧舱概念下跌0.21%，位居概念板块跌幅榜前列，板块内，创新医疗、国际医 学等跌幅居前，股价上涨的有6只，涨幅居前的有大湖股份、澳洋健康、三星医疗等，分别上涨 0.66%、0.43%、0.37%。 今日涨跌幅居前的概念板块 高压氧舱概念资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 601567 | 三星医疗 | 0.37 | 2.18 | -6080.45 | | 002173 | 创新医疗 | -2.00 | 13.41 | -5739.38 | | 000516 | 国际医学 | -0.80 | 1.13 | -1253.44 | | 688425 | 铁建重工 | 0.19 | 0.37 | -1145.79 | | 000919 | 金陵药业 | 0.00 | 1.93 | -847.21 | | 002172 | 澳洋健康 | 0.43 | 3.54 | -745.18 | | 600257 | 大湖股份 | 0.66 | 2.82 | -648. ...

澳洋健康公告称，2025年9月15日，悦升科技与澳洋集团签署协议，澳洋集团将1.53亿股（占比20%） 转让给悦升科技，同时放弃5%表决权。11月6日，股份过户登记完成。本次权益变动后，控股股东由澳 洋集团变更为悦升科技，实际控制人由沈学如变更为张家港经开区管委会。财务顾问东吴证券核查认 为，本次权益变动实施程序合规，相关方依法规范运作，收购人履行承诺且未违反后续计划，公司未为 收购人及其关联方提供担保或借款。 ...

东吴证券股份有限公司 关于 江苏澳洋健康产业股份有限公司 详式权益变动报告书 东吴证券股份有限公司（以下简称"本财务顾问"）接受悦升科技的委托， 担任其本次权益变动的财务顾问。2025年9月16日，上市公司公告了《详式权益 变动报告书》。根据《上市公司收购管理办法（2025年修正）》第七十一条， 本财务顾问持续督导期为2025年9月16日至收购完成后12个月。澳洋健康于2025 年10月31日披露了2025年三季度报告。根据《上市公司收购管理办法》等法律 法规的规定，通过日常沟通，并结合澳洋健康定期报告，本财务顾问出具本持 续督导意见。 本持续督导意见不构成对上市公司的任何投资建议；投资者根据本持续督 导意见所做出的任何投资决策而产生的相应风险，本财务顾问不承担任何责任。 本财务顾问未委托或授权其他任何机构或个人提供在本持续督导意见中列载的 信息和对本持续督导意见做任何解释或者说明，同时本财务顾问提请投资者认 真阅读上市公司发布的2025年三季度报告及其他信息披露文件。 释义 之 声明 2025年三季度持续督导意见 2025年9月15日，张家港悦升科技合伙企业（有限合伙）（以下简称"悦升 科技"）与江苏澳洋健 ...

Core Viewpoint - Jiangsu Aoyang Health Industry Co., Ltd. has completed the transfer of 20% of its shares to Zhangjiagang Yuesheng Technology Partnership, marking a shift from private to local state-owned control, which may enhance its market position and client trust [1][2][3] Group 1: Share Transfer Details - Aoyang Health's original controlling shareholder, Aoyang Group, transferred 20% of its shares, totaling 153 million shares, at a price of 3.87 yuan per share, amounting to a total of 593 million yuan [1] - The transfer was officially completed on November 6, 2025, with the new controlling entity being Zhangjiagang Economic and Technological Development Zone Management Committee [1] Group 2: Financial Performance - In the first three quarters of 2025, Aoyang Health reported a net profit attributable to shareholders of 40.11 million yuan, a year-on-year increase of 3.71% [2] - The net profit for the third quarter reached 8.56 million yuan, a significant increase of 533.86% compared to the same period last year, marking a new high for recent years [2] Group 3: Strategic Implications of Control Change - The change in control to a local state-owned entity may provide Aoyang Health with enhanced credibility and trust from clients, particularly those with government collaboration interests [2] - The new controlling entity's diverse industry background could facilitate resource integration, potentially enhancing Aoyang Health's capabilities in areas like remote healthcare and smart health monitoring [3] - The shift aligns with national policies promoting integrated medical and elderly care, positioning Aoyang Health to leverage new market opportunities and improve competitive advantage [3]

Core Insights - The company has achieved significant growth in profitability, with a net profit of 8.56 million yuan in Q3 2025, marking a substantial increase of 533.86% year-on-year, reaching a new high for the same period in recent years [1] - For the first three quarters of 2025, the cumulative net profit attributable to shareholders reached 40.11 million yuan, reflecting a year-on-year growth of 3.71%, demonstrating strong operational resilience despite short-term revenue adjustments [1] - The company’s core business profitability has improved, with a net profit of 2.35 million yuan in Q3 2025, up 63.23% year-on-year, indicating a substantial enhancement in core business performance [1] Profitability and Efficiency - The gross profit margin for the first three quarters of 2025 remained stable at 14.27%, while the net profit margin in Q3 increased to 1.91%, up 1.57 percentage points year-on-year, showcasing improved profitability quality during revenue structure adjustments [2] - The company has established a medical consortium centered around Aoyang Hospital, with over 2,300 total beds, covering comprehensive medical and rehabilitation services, thus forming a strong competitive advantage in the regional healthcare market [2] Shareholding Changes - The company’s shareholding change has been a focal point, with the controlling shareholder, Aoyang Group, transferring 20% of its shares to Zhangjiagang Yuesheng Technology Co., Ltd. for a total price of 593 million yuan, which has been completed [3] - Following the change in control, the new shareholder is expected to provide policy resource support, expand financing channels, and enhance regional business collaboration, thereby optimizing the company’s governance structure and strengthening its capital base for future development [3]

江苏澳洋健康产业股份有限公司 关于控股股东协议转让股份完成过户登记暨公司控股股东、实际控制人变更的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-34 关于控股股东协议转让股份完成过户登记暨公司 控股股东、实际控制人变更的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）于 今日收到张家港悦升科技合伙企业（有限合伙）（以下简称"悦升科技"）的通 知，获悉其协议转让公司股份事宜已完成过户登记手续。具体情况如下： 一、本次交易的基本情况 公司原控股股东澳洋集团有限公司（以下简称"澳洋集团"）、实际控制人 沈学如、实际控制人的一致行动人沈卿于 2025 年 9 月 15 日与张家港悦升科技合 伙企业（有限合伙）签署了《股份转让协议》。澳洋集团拟通过协议转让方式转 让公司 20%股份，共计 153,146,472 股。转让价格为 3.87 元/股，合计总金额为 592,676,846.64 元。 本次权益变动不构成关联交易，不触及要约收购。本次权益变动完成后，悦 升科技 ...

证券日报网讯 11月6日晚间，澳洋健康发布公告称，公司近日接到持股5%以上股东澳洋集团有限公司 （以下简称"澳洋集团"）的通知，获悉澳洋集团所持有公司的部分股份解除质押，本次解除质押股数为 15，000，000股。 （文章来源：证券日报） ...

公告显示，本次股份转让事项完成后，公司控股股东、实际控制人发生变更，公司控股股东由澳洋集团 变更为悦升科技，公司的实际控制人由沈学如变更为张家港经济技术开发区管委会。 北京商报讯（记者 丁宁）11月6日晚间，澳洋健康（002172）发布公告称，公司于今日收到张家港悦升 科技合伙企业（有限合伙）（以下简称"悦升科技"）的通知，获悉其协议转让公司股份事宜已完成过户 登记手续。 ...

（编辑 任世碧） 证券日报网讯 11月6日晚间，澳洋健康发布公告称，公司原控股股东澳洋集团有限公司（简称"澳洋集 团"）、实际控制人沈学如、实际控制人的一致行动人沈卿于2025年9月15日与张家港悦升科技合伙企业 （有限合伙）（简称"悦升科技"）签署了《股份转让协议》。澳洋集团拟通过协议转让方式转让公司 20%股份，共计153，146，472股。转让价格为3.87元/股，合计总金额为592，676，846.64元。本次权 益变动不构成关联交易，不触及要约收购。本次权益变动完成后，悦升科技将持有公司股份153，146， 472股，约占公司总股本的20.00%。公司控股股东将由澳洋集团变更为悦升科技，公司的实际控制人将 由沈学如变更为张家港经济技术开发区管委会。公司于今日收到张家港悦升科技合伙企业（有限合伙） 的通知，获悉其协议转让公司股份事宜已完成过户登记手续。 ...

Core Points - Aoyang Health (SZ 002172) announced the completion of a share transfer, with 153,146,472 shares (20.00% of total shares) transferred to Zhangjiagang Yuesheng Technology Partnership, changing the controlling shareholder from Aoyang Group to Yuesheng Technology [1] - The actual controller of the company has changed from Shen Xueru to the Management Committee of Zhangjiagang Economic and Technological Development Zone [1] - For the first half of 2025, Aoyang Health's revenue composition was 52.49% from medical services and 47.51% from pharmaceutical logistics [1] - As of the announcement, Aoyang Health's market capitalization is 3.4 billion yuan [1]